Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03GLM
|
|||
| Former ID |
DIB015633
|
|||
| Drug Name |
BMS-210285
|
|||
| Synonyms |
UNII-WS7S13Q9RH; WS7S13Q9RH; CHEMBL60116; BMS-210285; 344607-69-8; SCHEMBL13550990; BDBM50073046; Methanesulfonamide, N-(5-((1R)-2-(((1R)-2-(3-chlorophenyl)-1-(4-(difluoromethoxy)phenyl)ethyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)-; N-(5-{(R)-2-[(R)-2-(3-Chloro-phenyl)-1-(4-difluoromethoxy-phenyl)-ethylamino]-1-hydroxy-ethyl}-2-hydroxy-phenyl)-methanesulfonamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Terminated | [1] | |
| Company |
Bristol-Myers Squibb Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H25ClF2N2O5S
|
|||
| Canonical SMILES |
CS(=O)(=O)NC1=C(C=CC(=C1)C(CNC(CC2=CC(=CC=C2)Cl)C3=CC=C(C=C3)OC(F)F)O)O
|
|||
| InChI |
1S/C24H25ClF2N2O5S/c1-35(32,33)29-21-13-17(7-10-22(21)30)23(31)14-28-20(12-15-3-2-4-18(25)11-15)16-5-8-19(9-6-16)34-24(26)27/h2-11,13,20,23-24,28-31H,12,14H2,1H3/t20-,23+/m1/s1
|
|||
| InChIKey |
DSEGFUSAJVUFLK-OFNKIYASSA-N
|
|||
| CAS Number |
CAS 344607-69-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-3 (ADRB3) | Target Info | Agonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Salivary secretion | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta3 adrenergic receptor signaling pathway | ||||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010623) | |||
| REF 2 | CA patent application no. 509835, Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.